Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: GOG 0213 Phase III randomized controled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum sensitive recurent ovarian peritoneal primary and fallopi

 


GOG 0213 Phase III randomized controled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum sensitive recurent ovarian peritoneal primary and fallopi


Trial Focus

Female Reproductive Cancer

Objective

         Clinical trial of Carboplatin and Paclitaxel administered by IV, which is considered standard of care and Bevacizumab administered by IV and is investigational.

IRB Protocol #

07-1235

Trial Status

OPEN

Principle Investigator

SAKETH GUNTUPALLI

Sponsor

GOG

Contact

REBECCA KISSANE at (720)848-7202 or REBECCA.KISSANE@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last up to nine months. A follow up period that will continue for the rest of your life. // Eligibility criteria include but are not limited to 18 years or older with ovarian, fallopian tube or peritoneal primary cancer.Eligibility criteria include but are not limited to 18 years or older with ovarian, fallopian tube or peritoneal primary cancer.